Skip to content
10-Q

Quarterly Report

CEREVEL THERAPEUTICS HOLDINGS, INC.

0000950170-24-055701

← back to feed
Filed
May 8, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Apr 26, 2024 182.19M sh
Shares Diluted Q1 2024 · Mar 31, 2024 181.61M sh
Shares Diluted Q1 2024 · Mar 31, 2023 156.65M sh
Capex Q1 2024 · Mar 31, 2024 $271K
Capex Q1 2024 · Mar 31, 2023 $336K
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$119.67M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$94.92M
Long Term Debt Q1 2024 · Mar 31, 2024 $375.19M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $320.44M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $416.47M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $153.82M
Stockholders Equity Q1 2024 · Mar 31, 2024 $564.46M
Stockholders Equity Q1 2024 · Dec 31, 2023 $673.75M
Stockholders Equity Q1 2024 · Mar 31, 2023 $431.71M
Stockholders Equity Q1 2024 · Dec 31, 2022 $521.24M
Current Liabilities Q1 2024 · Mar 31, 2024 $84.1M
Current Liabilities Q1 2024 · Dec 31, 2023 $92.18M
Total Liabilities Q1 2024 · Mar 31, 2024 $562.89M
Total Liabilities Q1 2024 · Dec 31, 2023 $569.55M
Current Assets Q1 2024 · Mar 31, 2024 $859.58M
Current Assets Q1 2024 · Dec 31, 2023 $1.01B
Total Assets Q1 2024 · Mar 31, 2024 $1.13B
Total Assets Q1 2024 · Dec 31, 2023 $1.24B
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.73
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.67
Eps Basic Q1 2024 · Mar 31, 2024 −$0.73
Eps Basic Q1 2024 · Mar 31, 2023 −$0.67
Sga Expense Q1 2024 · Mar 31, 2024 $36.23M
Sga Expense Q1 2024 · Mar 31, 2023 $21.37M
Rd Expense Q1 2024 · Mar 31, 2024 $106.43M
Rd Expense Q1 2024 · Mar 31, 2023 $78.18M
Net Income Q1 2024 · Mar 31, 2024 −$131.91M
Net Income Q1 2024 · Mar 31, 2023 −$104.29M
Operating Income Q1 2024 · Mar 31, 2024 −$142.66M
Operating Income Q1 2024 · Mar 31, 2023 −$99.55M